Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Conferences in February

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that members of company management or...
January 22, 2018 07:00 ET | Source: uniQure Inc.

uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington’s disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
January 08, 2018 07:00 ET | Source: uniQure Inc.

uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value

~ Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End ~ ~ AMT-130 Expected to be First AAV-Based Gene Therapy for Huntington’s Disease to Enter...
December 18, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
December 11, 2017 16:01 ET | Source: uniQure Inc.

uniQure Added to NASDAQ Biotechnology Index

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
December 11, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

– Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity at Up to Two Years of Follow-Up – – Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds,...
December 09, 2017 09:00 ET | Source: uniQure Inc.

uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting

Non-human primate study of AMT-061 utilizing FIX-Padua shows 6.5-fold increase in FIX clotting activitycompared to AMT-060 Data supports nonclinical comparability plan agreed upon with FDA ...
November 01, 2017 09:10 ET | Source: uniQure Inc.

uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
November 01, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 31, 2017 16:02 ET | Source: uniQure Inc.

uniQure Announces Multiple Company Presentations at Upcoming November Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...

keyboard_arrow_left Previous Page